<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00648336</url>
  </required_header>
  <id_info>
    <org_study_id>MERC-0360</org_study_id>
    <nct_id>NCT00648336</nct_id>
  </id_info>
  <brief_title>Fasting Study of Mercaptopurine 50 mg and Purinethol® Tablets 50 mg</brief_title>
  <official_title>Single-Dose Fasting In Vivo Bioequivalence Study of Mercaptopurine (50 mg; Mylan) and Purinethol® Tablets (50 mg; Gate) in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mylan Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mylan Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The objective of this study was to investigate the bioequivalence of Mylan's mercaptopurine&#xD;
      50 mg tablets to Gate's Purinethol® 50 mg tablets following a single, oral 50 mg (1 x 50 mg)&#xD;
      dose administered under fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">December 2003</completion_date>
  <primary_completion_date type="Actual">December 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence</measure>
    <time_frame>within 30 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mercaptopurine 50 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Purinethol® Tablets 50 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mercaptopurine 50 mg</intervention_name>
    <description>50mg, single dose fasting</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Purinethol® Tablets 50 mg</intervention_name>
    <description>50mg, single dose fasting</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 18 years and older.&#xD;
&#xD;
          2. Sex: Male&#xD;
&#xD;
          3. Volunteers are to be sterile (documentation required) or during the course of the&#xD;
             study, from study screen until 3 months after study exit, non-sterile male volunteers&#xD;
             must use a spermicide-containing barrier method of contraception to prevent the&#xD;
             pregnancy of their sexual partner. This advice should be documented in the informed&#xD;
             consent form.&#xD;
&#xD;
          4. Weight: At least 60 kg (132 lbs.) and within 15% of Ideal Body Weight (IBW), as&#xD;
             referenced by the Table of &quot;&quot;Desirable Weights of Adults&quot;&quot; Metropolitan Life Insurance&#xD;
             Company, 1999 (See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS).&#xD;
&#xD;
          5. All subjects should be judged normal and healthy during a pre-study medical evaluation&#xD;
             (physical examination, laboratory evaluation, 12-lead ECG, hepatitis B and hepatitis C&#xD;
             tests, HIV test, and urine drug screen including amphetamine, barbiturates,&#xD;
             benzodiazepine, cannabinoid, cocaine, opiate screen, phencyclidine, and methadone)&#xD;
             performed within 14 days of the initial dose of study medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Institutionalized subjects will not be used.&#xD;
&#xD;
          2. Social Habits:&#xD;
&#xD;
               1. Use of any tobacco products within 1 year of the start of the study.&#xD;
&#xD;
               2. Ingestion of any alcoholic, caffeine- or xanthine-containing food or beverage&#xD;
                  within the 48 hours prior to the initial dose of study medication.&#xD;
&#xD;
               3. Ingestion of any vitamin or herbal supplements within 7 days prior to the initial&#xD;
                  dose of the study medication.&#xD;
&#xD;
               4. Any recent, significant change in dietary or exercise habits.&#xD;
&#xD;
               5. History of drug and/or alcohol abuse within 1 year of the start of the study.&#xD;
&#xD;
               6. A positive result for any drug in the urine drug screen.&#xD;
&#xD;
          3. Medications:&#xD;
&#xD;
               1. Use of any medication within the 14 days prior to the initial dose of study&#xD;
                  medication.&#xD;
&#xD;
               2. Use of any medication known to alter hepatic enzyme activity within 28 days prior&#xD;
                  to the initial dose of study medication.&#xD;
&#xD;
               3. Use of allopurinol or aminosalicylates (e.g. olsalazine, mesalamine,&#xD;
                  sulfasalazine) within 3 months of the start of the study.&#xD;
&#xD;
          4. Diseases:&#xD;
&#xD;
               1. History of any significant chronic disease and/or hepatitis.&#xD;
&#xD;
               2. Acute illness at the time of either the pre-study medical evaluation or dosing.&#xD;
&#xD;
               3. A positive HIV, hepatitis B, or hepatitis C test.&#xD;
&#xD;
          5. Abnormal and clinically significant laboratory test results:&#xD;
&#xD;
               1. Clinically significant deviation from the Guide to Clinically Relevant&#xD;
                  Abnormalities (See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS).&#xD;
&#xD;
               2. Abnormal and clinically relevant ECG tracing.&#xD;
&#xD;
               3. Abnormal liver function tests (i.e. ALT (SGPT), AST (SGOT), alkaline phosphatase,&#xD;
                  bilirubin).&#xD;
&#xD;
          6. Donation or loss of a significant volume of blood or plasma (&gt; 450 mL) within 28 days&#xD;
             prior to the initial dose of study medication.&#xD;
&#xD;
          7. Subjects who have received an investigational drug within 30 days prior to the initial&#xD;
             dose of study medication.&#xD;
&#xD;
          8. Allergy or hypersensitivity to mercaptopurine or other related products.&#xD;
&#xD;
          9. History of difficulties in swallowing, or any gastrointestinal disease which could&#xD;
             affect the drug absorption.&#xD;
&#xD;
         10. Consumption of grapefruit or grapefruit containing products within 7 days of drug&#xD;
             administration.&#xD;
&#xD;
         11. Family history of a deficiency in the enzyme thiopurine methyltransferase.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James D Carlson, Pharm. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRACS Institute Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRACS Institute, Ltd.</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mpibiostudies.com</url>
    <description>Mylan Pharmaceuticals Inc. - Clinical Trial Results</description>
  </link>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/about.cfm</url>
    <description>Daily Med - posting of most recent submitted labelling to the Food and Drug Administration (FDA) and currently in use</description>
  </link>
  <link>
    <url>http://www.fda.gov/opacom/7alerts.html</url>
    <description>Recalls, Market Withdrawals and Safety Alerts</description>
  </link>
  <verification_date>March 2008</verification_date>
  <study_first_submitted>March 30, 2008</study_first_submitted>
  <study_first_submitted_qc>March 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2008</study_first_posted>
  <last_update_submitted>March 31, 2008</last_update_submitted>
  <last_update_submitted_qc>March 31, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2008</last_update_posted>
  <responsible_party>
    <name_title>Will Sullvan, Global Head of Product Risk and Safety Management</name_title>
    <organization>Mylan Inc.</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mercaptopurine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

